7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $36000 | -$274M | 0.0% | -748344.4% | -$151M | — | $60M |
| 2024 | $61000 | -$343M | 0.0% | -588123.0% | -$163M | — | $106M |
| 2023 | $130000 | -$235M | 0.0% | -190006.2% | -$166M | — | $146M |
| 2022 | $85M | -$183M | 0.0% | -220.9% | -$194M | — | $124M |
| 2021 | $11M | -$250M | 0.0% | -2016.7% | -$192M | — | $294M |
| 2020 | $8M | -$204M | 0.0% | -2732.6% | -$212M | — | $140M |
| 2019 | $657000 | -$129M | 0.0% | -15538.7% | $23M | — | $97M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2000 | -$24M | 0.0% | -2213050.0% | -$39M | — | $91M |
| Dec '25 | $6000 | -$141M | 0.0% | -2127400.0% | -$33M | — | $60M |
| Sep '25 | $15000 | -$39M | 0.0% | -248353.3% | -$29M | — | $124M |
| Jun '25 | $8000 | -$43M | 0.0% | -589250.0% | -$35M | — | $99M |
| Mar '25 | $7000 | -$52M | 0.0% | -819528.6% | -$55M | — | $120M |
| Dec '24 | $11000 | -$192M | 0.0% | -1828609.1% | -$47M | — | $106M |
| Sep '24 | $34000 | -$45M | 0.0% | -148544.1% | -$35M | — | $100M |
| Jun '24 | $13000 | -$46M | 0.0% | -396369.2% | -$38M | — | $133M |
| Mar '24 | $3000 | -$61M | 0.0% | -1852500.0% | -$42M | — | $126M |
| Dec '23 | $13000 | -$53M | 0.0% | -457753.8% | -$41M | — | $146M |
| Sep '23 | $25000 | -$51M | 0.0% | -236156.0% | -$38M | — | $286M |
| Jun '23 | $27000 | -$64M | 0.0% | -244092.6% | -$40M | — | $224M |
| Mar '23 | $65000 | -$67M | 0.0% | -96240.0% | -$48M | — | $109M |
| Dec '22 | $48M | -$8M | 0.0% | -30.6% | -$45M | — | $124M |
| Sep '22 | $3000 | -$70M | 0.0% | -2214566.7% | -$40M | — | $116M |
| Jun '22 | $36M | -$36M | 0.0% | -104.3% | -$52M | — | $206M |
| Mar '22 | $553000 | -$68M | 0.0% | -12400.7% | -$58M | — | $223M |
| Dec '21 | $3M | -$84M | 0.0% | -1684.5% | -$43M | — | $294M |
| Sep '21 | $3M | -$49M | 0.0% | -1784.4% | -$37M | — | $394M |
| Jun '21 | $3M | -$63M | 0.0% | -2386.1% | -$58M | — | $564M |
How the market has priced LYEL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Lyell Immunopharma, Inc.'s revenue has declined 65.9% per year. These are computed facts, not advice.
As of FY2025, Lyell Immunopharma, Inc. reported — of total debt against $60M of cash.
In FY2025, gross margin was —, operating margin -748344.4%, and net margin -762355.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.